



VACCINE ADVISORY COMMITTEE

SheAnne Allen October 18, 2018

Vaccine Management Update

- Best Practices in Vaccine Storage, Handling & Accountability Workgroup
- Vaccine Choice
- Hepatitis A Planning
- Gardasil
- Shingrix
- Hepatitis B Update
- Influenza 2017-2018, 2018-2019

Best Practices in Vaccine Storage, Handling, and Accountability Work

- Close to a final policy
- Workgroup will be editing during the next month
- Share with VAC
- Developing roll-out plan
- Next workgroup meeting beginning of December



Vaccine Choice

October 15th – 31st.

Providers choose the preferred vaccine presentations for their office.

Meningococcal B vaccine will be an option.

Both Adacel (latex free) and Boostrix will only be offered in the pre-filled syringe format.

Reminder about storage capacity for these doses.

Hepatitis A Planning

DOH workgroup to develop plan

- Local jurisdiction activities
- What information do providers need?
- Are providers confident they can diagnose properly?
- Resources/tools available



Hepatitis B Vaccine Supply Update

Though we continue to have sufficient hepatitis B vaccine to supply all enrolled providers with their full vaccine orders, providers may receive doses that are not of their preferred presentation.

Remember, although the antigen content differs between the two hepatitis B vaccines (Engerix and Recombivax HB), the two vaccines are interchangeable.

Providers must always follow the manufacturer's dosage recommendations, which may vary by product.

For updates on vaccine supply, see <u>CDC Current Vaccine</u> Shortages and Delays.

FDA Expanded Use of Gardasil

FDA approved the expanded use of Gardasil 9 to include individuals ages 27 through 45 years.

Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine.

For more information, se the FDA's Approval <u>Letter - Gardasil 9</u> and view the complete <u>FDA</u> press release.



Shingrix

Shingrix Shipping Delays

Continue to have ordering limits and intermittent shipping delays for GSK's Shingrix vaccine (Recombinant Zoster vaccine) due to high demand.

Important that patients still complete the **2-dose series**. If more than 6 months have elapsed since the first dose, the patient should receive the second dose as soon as possible. Do not restart the vaccine series, and do not substitute Zostavax (zoster vaccine live) for the second dose of Shingrix.

<u>Vaccine Finder</u> tool can help locate other providers who have Shingrix in stock.



Influenza 2017-2018 Summary

- 690,000 doses ordered
- 331,130 doses available
- Flu doses received at depot 8/13/18-10/?/18
- Flu orders approved starting 8/27/18



2018-2019 Influenza Season

0.25mL Fluzone Availability:

- 117,000 doses (100%) allocated
- 43,580 doses available for ordering

5.0mL multi-dose Fluzone **Availability:**

- 227,000 doses (100%) allocated
- 140,320 doses available for ordering

.5mL FluLaval Availability:

- 269,300 doses (88%) allocated
- 130,760 doses available for ordering

<u>0.2mL single dose FluMist</u> **Availability:**

- 20,000 doses (100%) allocated
- 16,510 doses available for ordering

SheAnne Allen, MPH, MCHES Vaccine Management Section Manager

Sheanne.allen@doh.wa.gov 360-236-3578

